ORUKA THERAPEUTICS INC

Insider buying and selling by Oruka Therapeutics’ leadership shows confidence in its gene‑targeted heart‑failure platform, signaling a promising upside for investors.

Oruka Therapeutics insider sells 51k shares under a Rule 10b5‑1 plan amid a 628% year‑to‑date rally—what it means for volatility, cash flow, and future growth.

Oruka Therapeutics insider trades by CMO Joana Gonçalves show disciplined buy‑low, sell‑high activity that signals leadership confidence and long‑term upside for the company.

Insightful July 13 insider trades by Oruka Therapeutics’ SVP show disciplined liquidity management, modest net sale, and continued long‑term confidence in a high‑growth biotech pipeline.

Oruka insider trading: Carl Dambkowski’s Rule 10b5‑1 sales signal confidence, not weakness—solid pipeline, rising share price, and disciplined liquidity management keep the biotech growth play bright.

Aruka Therapeutics insider activity shows finance leader’s disciplined buys and sales under a Rule 10b5‑1 plan, signaling confidence amid biotech regulatory shifts.

Oruka Therapeutics insider buys reveal confidence amid capital strain: CMO’s 18% stake jump, market sentiment, and future milestones.

Oruka Therapeutics insider moves: COO buys low, sells via Rule 10b5‑1, showing confidence amid price swings and heart‑failure pipeline prospects.

Oruka insider buys 7,000 shares at $6.84‑$7.80 while selling higher‑priced shares, signaling confidence ahead of Phase‑1 data that could lift its negative‑P/E biotech into growth mode.